CY1110531T1 - 6-υποκατεστημενες-2,3,4,5-τετραϋδρο-1η-βενζο[d]αζεπινες ως αγωνιστες του υποδοχεα 5-ht2c - Google Patents
6-υποκατεστημενες-2,3,4,5-τετραϋδρο-1η-βενζο[d]αζεπινες ως αγωνιστες του υποδοχεα 5-ht2cInfo
- Publication number
- CY1110531T1 CY1110531T1 CY20091101025T CY091101025T CY1110531T1 CY 1110531 T1 CY1110531 T1 CY 1110531T1 CY 20091101025 T CY20091101025 T CY 20091101025T CY 091101025 T CY091101025 T CY 091101025T CY 1110531 T1 CY1110531 T1 CY 1110531T1
- Authority
- CY
- Cyprus
- Prior art keywords
- azepines
- benzo
- tetrahydro
- substituents
- receptor agonists
- Prior art date
Links
- 102000006902 5-HT2C Serotonin Receptor Human genes 0.000 title abstract 2
- 108010072553 5-HT2C Serotonin Receptor Proteins 0.000 title abstract 2
- 239000000018 receptor agonist Substances 0.000 title abstract 2
- 229940044601 receptor agonist Drugs 0.000 title abstract 2
- 150000001538 azepines Chemical class 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- -1 6-substituted 2,3,4,5-tetrahydro-1H-benzo[d]azepines Chemical class 0.000 abstract 1
- 208000019901 Anxiety disease Diseases 0.000 abstract 1
- 208000008589 Obesity Diseases 0.000 abstract 1
- 230000036506 anxiety Effects 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
- C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D223/16—Benzazepines; Hydrogenated benzazepines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Hospice & Palliative Care (AREA)
- Child & Adolescent Psychology (AREA)
- Pain & Pain Management (AREA)
- Gynecology & Obstetrics (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US71349505P | 2005-09-01 | 2005-09-01 | |
| EP06802858A EP1924560B1 (en) | 2005-09-01 | 2006-09-01 | 6-substituted- 2,3,4,5-tetrahydro-1h-benzo[d]azepines as 5-ht2c receptor agonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1110531T1 true CY1110531T1 (el) | 2015-04-29 |
Family
ID=37499682
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20091101025T CY1110531T1 (el) | 2005-09-01 | 2009-10-02 | 6-υποκατεστημενες-2,3,4,5-τετραϋδρο-1η-βενζο[d]αζεπινες ως αγωνιστες του υποδοχεα 5-ht2c |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US7994163B2 (enExample) |
| EP (1) | EP1924560B1 (enExample) |
| JP (1) | JP5165568B2 (enExample) |
| AT (1) | ATE438627T1 (enExample) |
| CA (1) | CA2619566C (enExample) |
| CY (1) | CY1110531T1 (enExample) |
| DE (1) | DE602006008323D1 (enExample) |
| DK (1) | DK1924560T3 (enExample) |
| ES (1) | ES2328520T3 (enExample) |
| PL (1) | PL1924560T3 (enExample) |
| PT (1) | PT1924560E (enExample) |
| SI (1) | SI1924560T1 (enExample) |
| WO (1) | WO2007028082A1 (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI0615033A2 (pt) * | 2005-09-01 | 2011-04-26 | Lilly Co Eli | composto, composição farmacêutica, e, uso de um composto |
| WO2007028132A2 (en) * | 2005-09-01 | 2007-03-08 | Eli Lilly And Company | 6-N-LINKED HETEROCYCLE-SUBSTITUTED 2,3,4,5-TETRAHYDRO-1H-BENZO[d]AZEPINES AS 5-HT2C RECEPTOR AGONISTS |
| EP2727585A1 (en) | 2006-05-16 | 2014-05-07 | Takeda Pharmaceutical Company Limited | In-vivo screening method |
| WO2007140213A1 (en) | 2006-05-26 | 2007-12-06 | Forest Laboratories Holdings Limited | Pyridoazepine derivatives |
| US20100266504A1 (en) | 2007-11-15 | 2010-10-21 | Takahiro Matsumoto | Condensed pyridine derivative and use thereof |
| EP3725775A1 (en) * | 2009-02-17 | 2020-10-21 | Syntrix Biosystems, Inc. | Pyridine- and pyrimidinecarboxamides as cxcr2 modulators |
| EP2608672B1 (en) | 2010-08-23 | 2020-12-16 | Syntrix Biosystems, Inc. | Aminopyridine- and aminopyrimidinecarboxamides as cxcr2 modulators |
| US20130267500A1 (en) | 2010-09-01 | 2013-10-10 | Arena Pharmaceuticals, Inc. | 5-ht2c receptor agonists in the treatment of disorders ameliorated by reduction of norepinephrine level |
| SG10201506865WA (en) * | 2010-09-01 | 2015-10-29 | Arena Pharm Inc | Non-hygroscopic salts of 5-ht2c agonists |
| MX2013002422A (es) * | 2010-09-01 | 2013-05-17 | Arena Pharm Inc | Sales de lorcaserina con acidos opticamente activos. |
| MX2013002430A (es) * | 2010-09-01 | 2013-07-22 | Arena Pharm Inc | Formas de dosis de disolucion de rápida de agonistas de 5-ht2c. |
| JP6440625B2 (ja) | 2012-11-14 | 2018-12-19 | ザ・ジョンズ・ホプキンス・ユニバーシティー | 精神分裂病を処置するための方法および組成物 |
| WO2015066344A1 (en) | 2013-11-01 | 2015-05-07 | Arena Pharmaceuticals, Inc. | 5-ht2c receptor agonists and compositions and methods of use |
| CN105622511B (zh) * | 2014-11-03 | 2018-01-23 | 北京瑞都医药科技有限公司 | 一种减肥药物及其制备方法 |
| US20210052600A1 (en) | 2017-12-27 | 2021-02-25 | Takeda Pharmaceutical Company Limited | Therapeutic agents for stress urinary incontinence and incotinence of feces |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4265890A (en) * | 1978-07-07 | 1981-05-05 | Smithkline Corporation | 6-Phenyl thio- and 6-cyclohexyl thio-2,3,4,5-tetrahydro-1H-3-benzazepines |
| EP0285287A3 (en) | 1987-03-23 | 1990-08-16 | Smithkline Beecham Corporation | 3-benzazepine compounds for use in treating gastrointestinal motility disorders |
| US4985352A (en) * | 1988-02-29 | 1991-01-15 | The Trustees Of Columbia University In The City Of New York | DNA encoding serotonin 1C (5HT1c) receptor, isolated 5HT1c receptor, mammalian cells expressing same and uses thereof |
| GB9116824D0 (en) * | 1991-08-05 | 1991-09-18 | Smithkline Beecham Corp | Chemical compounds |
| US5639748A (en) * | 1991-08-05 | 1997-06-17 | Smithkline Beecham Corporation | 6,9-disubstituted benzazepines having α-adrenoceptor blocking activity |
| WO1993004866A1 (fr) * | 1991-09-11 | 1993-03-18 | Canon Kabushiki Kaisha | Element de nettoyage ameliore pour tete de jet d'encre et dispositif a jet d'encre equipe d'un tel element de nettoyage |
| GB9119467D0 (en) * | 1991-09-12 | 1991-10-23 | Smithkline Beecham Corp | Chemical compounds |
| US5698766A (en) * | 1995-04-05 | 1997-12-16 | The Regents Of The University Of California | Transgenic animal model for testing drugs for treating eating disorders and epilepsy |
| EP1213017A3 (en) | 2000-12-05 | 2003-11-12 | Akzo Nobel N.V. | Use of a 5-HT2C receptor agonist for the treatment of hot flushes |
| JPWO2002074746A1 (ja) * | 2001-03-16 | 2004-07-08 | 山之内製薬株式会社 | ベンゾアゼピン誘導体 |
| DE60206762T2 (de) | 2001-07-13 | 2006-07-13 | Pharmacia & Upjohn Co. Llc, Kalamazoo | Hexahydroazepino(4,5-g)indole und -indoline als 5-ht rezeptor-liganden |
| CA2468010A1 (en) * | 2001-11-28 | 2003-06-05 | Pharmacia & Upjohn Company | Benzazepine derivatives and their use as 5-ht ligands |
| US6953787B2 (en) * | 2002-04-12 | 2005-10-11 | Arena Pharmaceuticals, Inc. | 5HT2C receptor modulators |
| JP4782003B2 (ja) | 2003-06-17 | 2011-09-28 | アリーナ ファーマシューティカルズ， インコーポレイテッド | ５ｈｔ２ｃレセプター関連疾患の処置に有用なベンズアゼピン誘導体 |
| DK2332921T3 (en) | 2003-06-17 | 2016-05-09 | Arena Pharm Inc | 8-Chloro-1-methyl-2,3,4,5-tetrahydro-1H-3benzazepine hydrochloride |
| TW200510324A (en) | 2003-08-11 | 2005-03-16 | Lilly Co Eli | 6-(2,2,2-trifluoroethylamino)-7-chiloro-2, 3, 4, 5-tetrahydro-1h-benzo[d]azepine as a 5-ht2c receptor agonist |
| WO2005042491A1 (en) | 2003-10-22 | 2005-05-12 | Arena Pharmaceuticals, Inc. | Benzazepine derivatives and methods of prophylaxis or treatment of 5ht2c receptor associated diseases |
| US20070275949A1 (en) * | 2003-10-22 | 2007-11-29 | Arena Pharmaceuticals, Inc. | Benzazepine Derivatives and Methods of Prophylaxis or Treatment of 5Ht2C Receptor Associated Diseases |
| EP2479168B1 (en) * | 2004-02-25 | 2014-04-09 | Eli Lilly And Company | 6-Substituted 2,3,4,5-Tetrahydro-1H-Benzo [d]Azepines as 5-HT2C Receptor Agonists |
| RS50996B (sr) | 2004-12-21 | 2010-10-31 | Arena Pharmaceuticals Inc. | Kristalni oblici (r)-8-hloro-1-metil-2,3,4,5-tetrahidro-1h-benzazepin hlorhidrat |
| KR101519441B1 (ko) | 2004-12-23 | 2015-05-12 | 아레나 파마슈티칼스, 인크. | 5ｈｔ２ｃ 수용체 조정물질 조성물 및 그의 사용 방법 |
| BRPI0615033A2 (pt) * | 2005-09-01 | 2011-04-26 | Lilly Co Eli | composto, composição farmacêutica, e, uso de um composto |
-
2006
- 2006-09-01 PT PT06802858T patent/PT1924560E/pt unknown
- 2006-09-01 PL PL06802858T patent/PL1924560T3/pl unknown
- 2006-09-01 AT AT06802858T patent/ATE438627T1/de active
- 2006-09-01 DK DK06802858T patent/DK1924560T3/da active
- 2006-09-01 CA CA2619566A patent/CA2619566C/en not_active Expired - Fee Related
- 2006-09-01 JP JP2008529335A patent/JP5165568B2/ja not_active Expired - Fee Related
- 2006-09-01 US US11/996,457 patent/US7994163B2/en not_active Expired - Fee Related
- 2006-09-01 DE DE602006008323T patent/DE602006008323D1/de active Active
- 2006-09-01 WO PCT/US2006/034334 patent/WO2007028082A1/en not_active Ceased
- 2006-09-01 EP EP06802858A patent/EP1924560B1/en not_active Not-in-force
- 2006-09-01 SI SI200630458T patent/SI1924560T1/sl unknown
- 2006-09-01 ES ES06802858T patent/ES2328520T3/es active Active
-
2009
- 2009-10-02 CY CY20091101025T patent/CY1110531T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| DK1924560T3 (da) | 2009-10-19 |
| DE602006008323D1 (de) | 2009-09-17 |
| PT1924560E (pt) | 2009-10-23 |
| WO2007028082A1 (en) | 2007-03-08 |
| CA2619566C (en) | 2013-08-13 |
| JP5165568B2 (ja) | 2013-03-21 |
| SI1924560T1 (sl) | 2010-01-29 |
| ATE438627T1 (de) | 2009-08-15 |
| US20080255092A1 (en) | 2008-10-16 |
| PL1924560T3 (pl) | 2009-12-31 |
| CA2619566A1 (en) | 2007-03-08 |
| EP1924560B1 (en) | 2009-08-05 |
| ES2328520T3 (es) | 2009-11-13 |
| EP1924560A1 (en) | 2008-05-28 |
| JP2009508818A (ja) | 2009-03-05 |
| US7994163B2 (en) | 2011-08-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1110531T1 (el) | 6-υποκατεστημενες-2,3,4,5-τετραϋδρο-1η-βενζο[d]αζεπινες ως αγωνιστες του υποδοχεα 5-ht2c | |
| UA85699C2 (en) | 6-substituted 2,3,4,5-tetrahydro-1h-benzo[d]azepines as 5-ht2c receptor agonists | |
| WO2007028083A3 (en) | 6-arylalkylamino- 2,3,4,5-tetrahydro-1h-benzo[d]azepines as 5-ht2c receptor agonists | |
| TW200510324A (en) | 6-(2,2,2-trifluoroethylamino)-7-chiloro-2, 3, 4, 5-tetrahydro-1h-benzo[d]azepine as a 5-ht2c receptor agonist | |
| WO2008050341A3 (en) | Novel psychotropic agents having glutamate nmda activity | |
| GB0504828D0 (en) | Therapeutic agents | |
| ATE538650T1 (de) | Cannabinoid-rezeptor-antagonisten / inverse agonisten zur behandlung von übergewicht | |
| WO2007028132A3 (en) | 6-N-LINKED HETEROCYCLE-SUBSTITUTED 2,3,4,5-TETRAHYDRO-1H-BENZO[d]AZEPINES AS 5-HT2C RECEPTOR AGONISTS | |
| CY1110486T1 (el) | 6-υποκατασταθεισες 2,3,4,5-τετραϋδρο-1η-βενζο[d]αζεπινες ως συναγωνιστες υποδοχεως 5-ηt2c | |
| NO20076344L (no) | Piperazin-piperidin-antagonister og agonister av 5-HT1A-reseptoren | |
| MX2010005649A (es) | Compuestos novedosos como ligandos del receptor canabinoide y sus usos. | |
| DE602005023197D1 (de) | -muscarinrezeptors | |
| ATE433966T1 (de) | Methylendipiperidinderivate | |
| MX2010009643A (es) | Derivados de 2-aminoquinolina como antagonistas del receptor 5-hidroxitriptamina (5a). | |
| EA200701978A1 (ru) | Способ получения опиоидных модуляторов | |
| MX2007004306A (es) | Compuestos biciclicos como antagonistas del receptor de la hormona concentradora de melanina selectivos para el tratamiento de la obesidad y trastornos relacionados. | |
| DE502007002185D1 (de) | Verwendung von zusammensetzungen enthaltend kappa-opioidrezeptor-antagonisten zur behandlung von dissoziativen störungen | |
| ATE455111T1 (de) | Einen azepin-kern enthaltende antagonisten des histaminrezeptors | |
| MX2010009403A (es) | Derivados de 2-aminoquinolina. | |
| MX2010009820A (es) | 2-aminoquinolinas como antagonistas del receptor 5-hidroxitriptamina 5a. | |
| WO2007115192A3 (en) | P2x7 antagonists to treat affective disorders | |
| ATE532514T1 (de) | Piperidin- und piperazinderivate | |
| CY1113558T1 (el) | 6-αρυλαλκυλαμινο-2,3,4,5-τετραϋδρο-1η-βενζοδιαζεπινες ως αγωνιστες υποδοχεα 5-ht2c | |
| DOP2004000972A (es) | 6-(2,2,2-trifluoroetilamino)-7-cloro-2,3,4,5-tetrahidro 1h-benzo[d] azepina como agonista del receptor 5-ht2c | |
| MX2010003926A (es) | Compuestos novedosos como ligandos del receptor de canabinoides. |